GSK Raises 2025 Profit Forecast as HIV and Cancer Drugs Drive Growth

GSK boosts annual profit forecast to 12% growth as specialty medicines outperform. CEO Emma Walmsley's final report shows strong Q3 results despite US vaccine challenges.